Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-380135 drug-drug interaction study with quinidine
NCT07305779Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SEP-380135 in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Maximum Observed Concentration of SEP-380135 and its Metabolites at 11 days, Area Under the Curve from Time Zero to Last Measurable Concentration of SEP-380135 and its Metabolites at 11 days and 2 more. Started Mar 2025; status: completed.
02
Drugs
SEP-380135
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07305779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07305779.